	US 11,850,280 B1
	Oral vaccine for peste-des-petits-ruminants virus
Jolieke Gerdy van Oosterwijk, Memphis, TN (US); Andrew Raymond Peters, Dumfries Galloway (GB); Douglas Steven Zatechka, Jr., Cordova, TN (US); Luciana Meirelles Richer, Memphis, TN (US); and Christopher Anthony Przybyszewski, Southaven, MS (US)
Assigned to US Biologic, Inc, Memphis, TN (US)
Filed by US BIOLOGIC, INC, Memphis, TN (US)
Filed on Mar. 31, 2021, as Appl. No. 17/218,939.
Claims priority of provisional application 63/007,275, filed on Apr. 8, 2020.
Int. Cl. A61K 39/155 (2006.01); C12N 15/75 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01)

CPC A61K 39/155 (2013.01) [C12N 7/00 (2013.01); C12N 15/75 (2013.01); A61K 2039/542 (2013.01); A61K 2039/55594 (2013.01); A61K 2039/6087 (2013.01); C12N 2760/18434 (2013.01)]

5 Claims

1. A vaccine for oral administration comprising: an expression vehicle comprising Bacillus subtilis expressing a hemagglutinin protein from Peste-des-Petits-Ruminants virus (PPRV).